Apimeds Pharmaceuticals US, Inc.

What they do

Apimeds is a development-stage biopharmaceutical company developing Apitox, a purified honeybee venom-based drug candidate for acute pain and inflammation associated with knee osteoarthritis, licensed from Apimeds Korea for the U.S. market. It operates its biopharmaceutical business through wholly owned subsidiary Lokahi Therapeutics. Through MindWave Innovations, it holds Bitcoin, Tether, and NILA tokens and participates in the MindWaveDAO blockchain ecosystem through continued NILA sales.

Revenue drivers

• Apitox — Clinical-stage product candidate; no revenue yet as it is not approved. Licensed from Apimeds Korea for U.S. commercialization in exchange for a sales royalty.
• Digital assets — Holds BTC, USDT, and NILA tokens; revenue potential from appreciation and NILA sales in the MindWaveDAO ecosystem. Subject to cryptocurrency market volatility.

Recent performance

For the three months ended March 31, 2026, net loss was $35 million (exact amount truncated in source). Annual net losses widened from $777,694 in 2023 to $1.4M in 2024 and $6.0M in 2025. Operating cash flow was negative $627,790 in 2023, $733,526 in 2024, and $8.9M in 2025. As of March 31, 2026, the company had cash and equivalents of $979,534, total assets of $141.2M, and accumulated deficit reflected in negative earnings.

Strategy

Management is advancing clinical development of Apitox to obtain FDA regulatory approval and commercialization. Simultaneously, it is pursuing the digital asset segment, aiming for appreciation of its cryptocurrency holdings and continued NILA sales on the MindWaveDAO blockchain. The company completed a merger with MindWave on December 1, 2025, making MindWave a wholly owned subsidiary and issuing Preferred Stock to MindWave holders. Financing through securities purchase agreements and conversions of convertible notes is part of its capital strategy.

Risks

• Clinical and regulatory risk — Apitox is not approved; failure to obtain FDA approval would prevent commercialization and revenue generation.
• Cryptocurrency volatility — Digital asset holdings are subject to significant price fluctuations, impacting financial results and liquidity.
• Going concern risk — Recurring operating losses and minimal cash ($979,534 at 2026-03-31) raise substantial doubt about ability to continue operations without additional financing.
• Dilution risk — The MindWave merger and conversion of preferred stock and convertible notes have led to substantial equity issuance, potentially diluting existing shareholders.

Outlook

Management's outlook depends on successful completion of clinical development and regulatory approvals for Apitox, plus the performance of the digital asset segment. They plan to seek additional financing through a combination of financing activities and operations. No specific revenue or profitability guidance is provided, but the company acknowledges it is not possible to predict outcomes of R&D or cryptocurrency market sentiment.